Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
June 2020
-
Media ReleaseNovartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment optionsBasel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for…
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profileEMA CHMP positive opinion paves way for Cosentyx® to become a first-line systemic treatment in pediatric psoriasis CHMP opinion based on two Phase III studies showing Cosentyx provides fast and…
-
Media ReleaseNovartis receives positive CHMP opinion for new Xolair® indication to treat severe chronic rhinosinusitis with nasal polypsIf approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-…
-
Key ReleaseNovartis Resolves Legacy FCPA InvestigationsBasel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA)…
-
Media ReleaseNovartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosisThe Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from…
-
Media ReleaseNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago 86% of tech professionals agree: the…
-
Media ReleaseNovartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research effortsStudy discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
-
Media ReleaseNovartis expands Africa Sickle Cell Disease program to Uganda and TanzaniaNew collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients…
-
Key ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritisFDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial…
-
Media ReleaseUS FDA approves updated Novartis Beovu® label, to include additional safety informationNovartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1 The…
-
Media ReleaseNovartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthmaOnce-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving…
-
Media ReleaseNovartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritisPhase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521 nr-axSpA…
Pagination
- ‹ Previous page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- …
- 88
- › Next page